571 related articles for article (PubMed ID: 16828124)
1. Effect of the selective 5-HT7 receptor antagonist SB 269970 in animal models of anxiety and depression.
Wesołowska A; Nikiforuk A; Stachowicz K; Tatarczyńska E
Neuropharmacology; 2006 Sep; 51(3):578-86. PubMed ID: 16828124
[TBL] [Abstract][Full Text] [Related]
2. Effects of the brain-penetrant and selective 5-HT6 receptor antagonist SB-399885 in animal models of anxiety and depression.
Wesołowska A; Nikiforuk A
Neuropharmacology; 2007 Apr; 52(5):1274-83. PubMed ID: 17320917
[TBL] [Abstract][Full Text] [Related]
3. Anxiolytic-like and antidepressant-like effects produced by the selective 5-HT6 receptor antagonist SB-258585 after intrahippocampal administration to rats.
Wesołowska A; Nikiforuk A; Stachowicz K
Behav Pharmacol; 2007 Sep; 18(5-6):439-46. PubMed ID: 17762512
[TBL] [Abstract][Full Text] [Related]
4. Potential anxiolytic and antidepressant effects of the selective 5-HT7 receptor antagonist SB 269970 after intrahippocampal administration to rats.
Wesołowska A; Nikiforuk A; Stachowicz K
Eur J Pharmacol; 2006 Dec; 553(1-3):185-90. PubMed ID: 17097082
[TBL] [Abstract][Full Text] [Related]
5. Behavioral effects of the beta3 adrenoceptor agonist SR58611A: is it the putative prototype of a new class of antidepressant/anxiolytic drugs?
Consoli D; Leggio GM; Mazzola C; Micale V; Drago F
Eur J Pharmacol; 2007 Nov; 573(1-3):139-47. PubMed ID: 17669397
[TBL] [Abstract][Full Text] [Related]
6. Effects of a selective 5-HT1B receptor agonist and antagonists in animal models of anxiety and depression.
Tatarczyńska E; Kłodzińska A; Stachowicz K; Chojnacka-Wójcik E
Behav Pharmacol; 2004 Dec; 15(8):523-34. PubMed ID: 15577451
[TBL] [Abstract][Full Text] [Related]
7. WAY-200070, a selective agonist of estrogen receptor beta as a potential novel anxiolytic/antidepressant agent.
Hughes ZA; Liu F; Platt BJ; Dwyer JM; Pulicicchio CM; Zhang G; Schechter LE; Rosenzweig-Lipson S; Day M
Neuropharmacology; 2008 Jun; 54(7):1136-42. PubMed ID: 18423777
[TBL] [Abstract][Full Text] [Related]
8. Behavioral profile of P2X7 receptor knockout mice in animal models of depression and anxiety: relevance for neuropsychiatric disorders.
Basso AM; Bratcher NA; Harris RR; Jarvis MF; Decker MW; Rueter LE
Behav Brain Res; 2009 Mar; 198(1):83-90. PubMed ID: 18996151
[TBL] [Abstract][Full Text] [Related]
9. Does rat global transient cerebral ischemia serve as an appropriate model to study emotional disturbances?
Bantsiele GB; Bentué-Ferrer D; Amiot N; Allain H; Bourin M; Reymann JM
Fundam Clin Pharmacol; 2004 Dec; 18(6):685-92. PubMed ID: 15548240
[TBL] [Abstract][Full Text] [Related]
10. Anxiolytic-like effects of MTEP, a potent and selective mGlu5 receptor agonist does not involve GABA(A) signaling.
Klodzinska A; Tatarczyńska E; Chojnacka-Wójcik E; Nowak G; Cosford ND; Pilc A
Neuropharmacology; 2004 Sep; 47(3):342-50. PubMed ID: 15275823
[TBL] [Abstract][Full Text] [Related]
11. Characterisation of the selective 5-HT1B receptor antagonist SB-616234-A (1-[6-(cis-3,5-dimethylpiperazin-1-yl)-2,3-dihydro-5-methoxyindol-1-yl]-1-[2'-methyl-4'-(5-methyl-1,2,4-oxadiazol-3-yl)biphenyl-4-yl]methanone hydrochloride): in vivo neurochemical and behavioural evidence of anxiolytic/antidepressant activity.
Dawson LA; Hughes ZA; Starr KR; Storey JD; Bettelini L; Bacchi F; Arban R; Poffe A; Melotto S; Hagan JJ; Price GW
Neuropharmacology; 2006 Jun; 50(8):975-83. PubMed ID: 16581092
[TBL] [Abstract][Full Text] [Related]
12. The anxiolytic-like activity of AIDA (1-aminoindan-1,5-dicarboxylic acid), an mGLu 1 receptor antagonist.
Kłodzińska A; Tatarczyńska E; Stachowicz K; Chojnacka-Wójcik E
J Physiol Pharmacol; 2004 Mar; 55(1 Pt 1):113-26. PubMed ID: 15082872
[TBL] [Abstract][Full Text] [Related]
13. Potential antidepressant-like effect of MTEP, a potent and highly selective mGluR5 antagonist.
Pałucha A; Brański P; Szewczyk B; Wierońska JM; Kłak K; Pilc A
Pharmacol Biochem Behav; 2005 Aug; 81(4):901-6. PubMed ID: 16040106
[TBL] [Abstract][Full Text] [Related]
14. Anxiolytic-like effect of group III mGlu receptor antagonist is serotonin-dependent.
Stachowicz K; Chojnacka-Wójcik E; Kłak K; Pilc A
Neuropharmacology; 2007 Feb; 52(2):306-12. PubMed ID: 17020774
[TBL] [Abstract][Full Text] [Related]
15. The anxiolytic-like effect of 5-HT1B receptor ligands in rats: a possible mechanism of action.
Chojnacka-Wójcik E; Kłodzińska A; Tatarczyńska E
J Pharm Pharmacol; 2005 Feb; 57(2):253-7. PubMed ID: 15720791
[TBL] [Abstract][Full Text] [Related]
16. Anxiolytic- and antidepressant-like properties of ketamine in behavioral and neurophysiological animal models.
Engin E; Treit D; Dickson CT
Neuroscience; 2009 Jun; 161(2):359-69. PubMed ID: 19321151
[TBL] [Abstract][Full Text] [Related]
17. On the mechanism of antidepressant-like action of berberine chloride.
Kulkarni SK; Dhir A
Eur J Pharmacol; 2008 Jul; 589(1-3):163-72. PubMed ID: 18585703
[TBL] [Abstract][Full Text] [Related]
18. Effects of combined administration of 5-HT1A and/or 5-HT1B receptor antagonists and paroxetine or fluoxetine in the forced swimming test in rats.
Tatarczyńska E; Kłodzińska A; Chojnacka-Wójcik E
Pol J Pharmacol; 2002; 54(6):615-23. PubMed ID: 12866716
[TBL] [Abstract][Full Text] [Related]
19. Effect of the adenosine A2a receptor antagonist 3,7-dimethyl-propargylxanthine on anxiety-like and depression-like behavior and alcohol consumption in Wistar Rats.
Thorsell A; Johnson J; Heilig M
Alcohol Clin Exp Res; 2007 Aug; 31(8):1302-7. PubMed ID: 17550371
[TBL] [Abstract][Full Text] [Related]
20. Some pharmacological properties of new analogs of MP 3022, the 5-HT1A receptor antagonist.
Chojnacka-Wójcik E; Kłodzińska A; Tatarczyńska E; Paluchowska MH
Pol J Pharmacol; 1999; 51(5):405-13. PubMed ID: 10817541
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
